Management of Non-metastatic Castration Resistant Prostate Cancer (nmCRPC): Putting current evidence into practice (POSTPONED to 18-01-2023)

Non metastatic castrate resistant benefit from the addition of drugs that all lead to major clinical improvement in RCT: a major delay in metastasis and a real increased survival. This with a maintained quality of life and a very acceptable toxicity profile. However how can we extrapolate the RCT to everyday practice? What about patient selection, and do the more sensitive imaging modalities have any role in this situation? What about bone health which remains a major component of the quality of life for these men?

In this webinar we will try to answer these specific questions.